Want to see TSE:MDNA full AI Analyst Report?
Top Page
Medicenna Therapeutics Corp
(TSX:MDNA)
Select Model
Select Model
Rating:46Neutral
Price Target:
C$0.40
▼(-14.47% Downside)
Action:Reiterated
Date:08/24/26
The score is primarily held down by weak financial performance (no revenue, large losses, and sustained cash burn with a shrinking equity base). Technicals are mixed with modest near-term stabilization but a longer-term downtrend, and valuation is constrained by negative earnings and no dividend yield data. Offsetting this, corporate updates point to continued pipeline progress and near-term clinical/regulatory catalysts.
Positive Factors
Clinical pipeline advancement
Progress across MDNA11 and bizaxofusp provides multiple clinical value drivers and may improve the company’s ability to demonstrate efficacy, attract partners, and advance programs toward later-stage development over the next several quarters.
Negative Factors
No commercial revenue
With no approved commercial product, Medicenna lacks recurring operating revenue to fund research and development. Its financial outlook therefore remains dependent on successful clinical execution, partnerships, grants, or additional capital rather than an established revenue base.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical pipeline advancement
Progress across MDNA11 and bizaxofusp provides multiple clinical value drivers and may improve the company’s ability to demonstrate efficacy, attract partners, and advance programs toward later-stage development over the next several quarters.
Read all positive factors
Medicenna Therapeutics Corp (MDNA) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$36.48M
Dividend YieldN/A
Average Volume (3M)47.91K
Price to Earnings (P/E)―
Beta (1Y)1.53
Revenue GrowthN/A
EPS Growth-33.27%
CountryCA
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.22
Shares Outstanding77,617,340
10 Day Avg. Volume50,780
30 Day Avg. Volume47,909
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)21.45
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$1.60Price Target Upside240.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.34
Revenue Forecast (FY)N/A
Medicenna Therapeutics Corp Business Overview & Revenue Model
Company Description
Medicenna Therapeutics Corp. is an immunotherapy firm focused on creating and commercializing Superkines and "empowered Superkines" to combat cancer and various other illnesses. Their primary candidate, MDNA55, an interleukin-4 (IL-4) empowered cy...
How the Company Makes Money
Medicenna Therapeutics does not appear to generate recurring revenue from product sales because its programs are in clinical development and it does not have an approved commercial product. As a result, the company’s funding has primarily been sup...
Medicenna Therapeutics Corp Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
46
Neutral
Cash Flow
21
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -75.00K | -77.00K | -55.00K | -5.00K | -38.00K | -40.00K |
| EBITDA | -22.99M | -23.63M | -12.97M | -16.30M | -22.54M | -17.25M |
| Net Income | -18.56M | -18.41M | -11.80M | 1.55M | -22.65M | -17.18M |
Balance Sheet | ||||||
| Total Assets | 8.25M | 8.45M | 28.38M | 36.45M | 23.46M | 42.25M |
| Cash, Cash Equivalents and Short-Term Investments | 5.69M | 6.25M | 24.84M | 33.60M | 20.54M | 40.38M |
| Total Debt | 104.00K | 119.00K | 168.00K | 0.00 | 0.00 | 34.00K |
| Total Liabilities | 6.58M | 5.97M | 9.29M | 6.96M | 2.62M | 4.11M |
| Stockholders Equity | 1.67M | 2.48M | 19.09M | 29.49M | 20.84M | 38.15M |
Cash Flow | ||||||
| Free Cash Flow | -14.33M | 0.00 | -16.52M | -12.66M | -23.58M | -15.31M |
| Operating Cash Flow | -18.81M | -17.92M | -16.49M | -12.66M | -23.58M | -15.31M |
| Investing Cash Flow | 2.00K | 2.00K | -33.00K | -13.05M | 10.05M | 5.01M |
| Financing Cash Flow | 3.82M | -19.00K | 23.49M | 24.76M | 3.88M | 18.26M |
Medicenna Therapeutics Corp Technical Analysis
Positive
0.47
Price Trends
0.40
Positive
0.46
Positive
0.71
Negative
Market Momentum
0.02
Negative
62.61
Neutral
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MDNA, the sentiment is Positive. The current price of 0.47 is above the 20-day moving average (MA) of 0.44, above the 50-day MA of 0.40, and below the 200-day MA of 0.71, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 62.61 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MDNA.
Medicenna Therapeutics Corp Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | C$91.14M | 20.98 | 15.04% | 6.94% | 4.11% | 88.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | C$264.14M | -4.59 | -71.28% | ― | ― | -6.00% | |
46 Neutral | C$36.48M | -2.13 | -360.29% | ― | ― | -33.27% | |
44 Neutral | C$69.29M | -24.00 | 74.79% | ― | ― | -15.53% |
* Healthcare Sector Average
TSE:MDNA
Medicenna Therapeutics Corp
0.47
-0.59
-55.66%
TSE:MSCL
Satellos Bioscience
12.45
4.53
57.20%
TSE:ARCH
Arch Biopartners
1.02
-0.63
-38.18%
TSE:COV
Covalon Technologies
3.30
1.15
53.49%
TSE:METX
ME Therapeutics Holdings, Inc.
2.50
-1.50
-37.50%
TSE:ONCO
Onco-Innovations Ltd.
1.47
0.00
0.00%
Medicenna Therapeutics Corp Corporate Events
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Medicenna Advances Superkine Pipeline With New Data and Regulatory Plans
Positive
Aug 14, 2026
Medicenna reported fiscal 2027 first-quarter results and said cash and cash equivalents stood at $5.7 million at June 30, 2026, slightly down from $6.3 million three months earlier. The company reiterated its focus on advancing its Superkine pipel...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.